




SUPPLEMENTARY FIGURES AND TABLES




Supplementary Figure S1: The relationship between PAK family member expression levels and endocrine-treated breast cancer patient outcome in the Metabric database. A. Kaplan-Meier plot of disease-specific survival in ER+, endocrine therapy only treated patients in the Metabric database stratified for high (red) and low (black) PAK1 expression levels ($n = 915$; median cut-off; Probe ILMN_1767365: HR = 1.21; 95% CI: 0.94–1.57; $P = 0.141$). B. Kaplan-Meier plot of disease-specific survival in ER+, endocrine therapy only treated patients in the Metabric database stratified for high (red) and low (black) PAK2 expression levels ($n = 915$; median cut-off; Probe ILMN_1712687: HR = 0.88; 95% CI: 0.68–1.15; $P = 0.348$). C. Kaplan-Meier plot of disease-specific survival in ER+, endocrine therapy only treated patients in the Metabric database stratified for high (red) and low (black) PAK3 expression levels ($n = 915$; median cut-off; Probe ILMN_2130218: HR = 1.02; 95% CI: 0.79–1.32; $P = 0.895$). D. Kaplan-Meier plot of disease-specific survival in ER+, endocrine therapy only treated patients in the Metabric database stratified for high (red) and low (black) PAK5 (gene named PAK7) expression levels ($n = 915$; median cut-off; Probe ILMN_1770938: HR = 0.90; 95% CI: 0.70–1.18; $P = 0.452$). E. Kaplan-Meier plot of disease-specific survival in ER+, endocrine therapy only treated patients in the Metabric database stratified for high (red) and low (black) PAK6 expression levels ($n = 915$; median cut-off; Probe ILMN_1708223: HR = 1.20; 95% CI: 0.92–1.57; $P = 0.188$).



Supplementary Figure S2: The relationship between PAK family member expression levels and endocrine or tamoxifen-only treated breast cancer patient outcome in KMplot database. A–E. Kaplan-Meier plot of disease-specific survival in ER+, endocrine therapy only treated patients in the KMplot database stratified for high (red) and low (black) PAK family member expression levels ($n = 725$; optimized cut-off; A: PAK1 Probeset 209615_s_at: HR = 1.34; 95% CI: 0.98–1.84; $P = 0.067$; B: PAK2 Probeset 208877_at: HR = 1.72; 95% CI: 1.26–2.34; $P = 0.00051$; C: PAK3 Probeset 214607_at: HR = 0.77; 95% CI: 0.56–1.06; $P = 0.11$; D: PAK5 (gene named PAK7) Probeset 210721_at: HR = 0.77; 95% CI: 0.56–1.06; $P = 0.11$; E: PAK6 Probeset 219461_at: HR = 1.52; 95% CI: 1.03–2.24; $P = 0.032$). F–J. Kaplan-Meier plot of disease-specific survival in ER+, tamoxifen-only treated patients in the KMplot database stratified for high (red) and low (black) PAK family member expression levels ($n = 650$; optimized cut-off; F: PAK1 Probeset 209615_s_at: HR = 1.23; 95% CI: 0.88–1.71; $P = 0.22$; G: PAK2 Probeset 208877_at: HR = 1.54; 95% CI: 1.11–2.14; $P = 0.0086$; H: PAK3 Probeset 214607_at: HR = 0.79; 95% CI: 0.55–1.14; $P = 0.21$; I: PAK5 (gene named PAK7) Probeset 210721_at: HR = 0.85; 95% CI: 0.6–1.2; $P = 0.37$; J: PAK6 Probeset 219461_at: HR = 1.39; 95% CI: 1.01–1.89; $P = 0.04$).



Supplementary Figure S3: PAK4 inhibition impairs ER α signaling in T47D cells. **A.** PAK4 depletion or functional inhibition of group II PAKs reduces ER α protein levels in T47D cells. T47D ER α positive human breast cancer cells were transfected with siControl or siPAK4 oligos (#1 or #2) for 72 h, or treated with 50 μ M GNE-2861 for 24 h. ER α , PAK4 and β -actin levels were determined by immunoblot. **B.** PAK4 depletion or functional group II PAK inhibition reduces the activity of estrogen receptor-induced signal transduction in T47D. T47D cells were transfected with siControl, siPAK4 oligos (#1 or #2), or treated with GNE-2861 as described in A. 24 h before measurement, cells were transfected with an ERE luciferase reporter. After 18 h, cells were treated with 10 nM E2 or vehicle, and an ERE-luc luciferase assay was carried out 6 h after E2 addition. Shown values represent mean \pm s.d. (n = 3), which is representative for three independent experiments. * - $P < 0.05$ for Flag-PAK4 group versus control, according to *t*-test.



Supplementary Figure S4: PAK4 depletion or functional group II PAK inhibition impairs cell proliferation in MCF-7 cells. MCF-7 cells were transfected with siControl, siPAK4 oligos (#1 or #2), or treated with GNE-2861. Cells were then treated with 10 nM E2 or vehicle for 6 h before fixation. EdU was added at a concentration of 10 μ M during the last 1 h. Flow cytometry histograms shows negative (M1) and EdU-positive (M2) cell populations and the fraction of EdU-positive cells is indicated.

Supplementary Table S1: qPCR primers used in this study. Column 1 contains the primer name and the information whether the primer is a forward or reverse primer. Column 2 contains the oligonucleotide sequence in 5' to 3' direction. Column 3 specifies in which figure the results related to this primer are displayed.

| Primer name | Sequence | Figure |
|-------------------------|---------------------------|--------|
| Neg Ctrl #1 Forward | TCTCTTCCTCAGCCCCTTTGT | 3D |
| Neg Ctrl #1 Reverse | GTACCAAGCACAGAGCAAATGG | 3D |
| Neg Ctrl #2 Forward | CACCATGTTTGGGAAGAGGAA | 3D |
| Neg Ctrl #2 Reverse | GCGGTGCTCGAAGTTGGA | 3D |
| Binding site #1 Forward | CAGGTCATGGGTACGGAAGTG | 3D |
| Binding site #1 Reverse | CGACCATTCCGAGGTCATTC | 3D |
| Binding site #2 Forward | GGTGAGGAGACGGCTTTAGCT | 3D |
| Binding site #2 Reverse | TCTGATTGTATCCTCTCCTGCTAAA | 3D |
| 36B4 Forward | GTGTTTCGACAATGGCAGCAT | 4C |
| 36B4 Reverse | GACACCCTCCAGGAAGCGA | 4C |
| PAK4 Forward | ATGTGGTGGAGATGTACAACAGCTA | 4C |
| PAK4 Reverse | GTTTCATCCTGGTGTGGGTGAC | 4C |
| ER α Forward | GCTACGAAGTGGGAATGATGAAAG | 4C |
| ER α Reverse | TCTGGCGCTTGTGTTTCAAC | 4C |
| ADORA1 Forward | TTCCACACCTGCCTCATGGT | 4C |
| ADORA1 Reverse | GCGGTCCACAGCAATTGC | 4C |
| Cyclin D1 Forward | CACGCGCAGACCTTCGT | 4C |
| Cyclin D1 Reverse | GGGCGGATTGGAAATGAAC | 4C |
| EGR3 Forward | GCCATTACAATCAGATGGCT | 4C |
| EGR3 Reverse | GCTCGAATAAGAGAGTTCCGGA | 4C |
| GREB1 Forward | ATCAGCTGCTCGGACTTGCTG | 4C |
| GREB1 Reverse | TGAGCTCCGGTCCTGACAGATG | 4C |
| IL-20 Forward | CGATGCTGCCTCCTGCG | 4C |
| IL-20 Reverse | GCTGCCTGAGGTTCCAGCTT | 4C |
| PDZK1 Forward | GCCAGGCTCATTTCATCAAAGA | 4C |
| PDZK1 Reverse | CCTCTAGCCCAGCCAAGTCA | 4C |
| PKIB Forward | GAGGCTCTCTCCGTGAAGGA | 4C |
| PKIB Reverse | TCCAATTGGTCTTGTGTTGTTTT | 4C |
| PS2 Forward | CATCGACGTCCCTCCAGAAGAG | 4C |
| PS2 Reverse | CTCTGGGACTAATCACCGTGCTG | 4C |

Supplementary Table S2: KMplot probeset selection for PAK family members. Column 1 contains probeset IDs. Column 2 contains probeset gene symbol and the Jetset status of the gene according to KMplot. Green probeset means it is the Jetset best probeset for a gene in the A arrays; Red probeset means it is not the Jetset best probe set for a gene in the B array. Column 3 contains probeset annotation in KMplot. For PAK2, PAK3 and PAK5, other names (synonyms) are also used in KMplot. The PAK6 probeset is also annotated as PAK5 probeset in KMplot. Column 4 contains probeset gene symbol according to the newest version of the hgu133a.db Bioconductor package (annotation for array A version 3.1.3). In column 1, the probeset used in this study for each PAK family member is highlighted in bold. The probeset selection was based on the correct gene annotation in the hgu133a.db Bioconductor package and the qualification as a KMplot green probeset.

| Probeset ID | Kmplot | Annotation by Kmplot | Annotation by hgu133a.db |
|--------------------|---------------------|--|--------------------------|
| 202161_at | PAK1 Green probeset | | PKN1 |
| 209615_s_at | PAK1 Green probeset | | PAK1 |
| 205962_at | PAK2 Red probeset | | PAK2 |
| 208875_s_at | PAK2 Red probeset | | PAK2 |
| 208876_s_at | PAK2 Red probeset | | PAK2 |
| 208877_at | PAK2 Green probeset | PAK2, also named PAK67 or PAKgamma | PAK2 |
| 208878_s_at | PAK2 Red probeset | | PAK2 |
| 202547_s_at | PAK3 Red probeset | | ARHGEF7 |
| 202548_s_at | PAK3 Green probeset | | ARHGEF7 |
| 214607_at | PAK3 Green probeset | PAK3, also named hPAK3, bPAK, MRX30 or MRX47 | PAK3 |
| 203154_s_at | PAK4 Green probeset | | PAK4 |
| 215326_at | PAK4 Red probeset | | PAK4 |
| 33814_at | PAK4 Red probeset | | PAK4 |
| 210721_s_at | PAK7 Green probeset | PAK5, also named PAK7, KIAA1264 | PAK7 |
| 213990_s_at | PAK7 Red probeset | | PAK7 |
| 219461_at | PAK6 Green probeset | also annotated as PAK5 probeset in Kmplot | PAK6 |

Supplementary Table S3: Metabric probe selection for PAK family members. Column 1 contains illumina probe IDs. Column 2 contains probe annotation in the Metabric database. Column 3 contains probeset interquartile range in the Metabric dataset. In column 1, for each PAK family member gene, the probe displaying the highest interquartile range was chosen for analysis and is highlighted in bold.

| Illumina Probe ID | Annotation | Interquartile range |
|---------------------|------------------------|---------------------|
| ILMN_1767365 | PAK1 | 0.74 |
| ILMN_1676385 | PAK2 | 0.47 |
| ILMN_1712687 | PAK2 | 0.49 |
| ILMN_2130218 | PAK3 | 0.18 |
| ILMN_1728887 | PAK4 | 0.57 |
| ILMN_1763187 | PAK4 | 0.20 |
| ILMN_2354673 | PAK4 | 0.35 |
| ILMN_1708223 | PAK6 | 0.77 |
| ILMN_1770938 | PAK7 (also named PAK5) | 0.20 |